Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604485 · ClinicalTrials.gov registry record · Phase 2
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
A Phase 2 study, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02604485 is a Phase 2 study that has completed, run by Xoma (US). The registered enrollment target is 10 participants.
The verdict
NCT02604485, a Phase 2 study, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated with congenital hyperinsulinism.
Interventions
- DRUG Cohort 4
- DRUG Cohort 3
- DRUG Cohort 2
- DRUG Cohort 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604485
The ClinicalTrials.gov registry entry for NCT02604485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cohort 4 is the first listed.
NCT02604485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02604485 about?
NCT02604485 is a clinical study titled "A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism". The purpose of this study is to evaluate the safety and clinical pharmacology of a single dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia associated with congenital hyperinsulinism.
What is the current status of trial NCT02604485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02604485?
The interventions under investigation include: Cohort 4 (DRUG), Cohort 3 (DRUG), Cohort 2 (DRUG), Cohort 1 (DRUG).
Who is sponsoring clinical trial NCT02604485?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.